

Table XXVIII-1

AGE-ADJUSTED AND AGE-SPECIFIC SEER CANCER INCIDENCE RATES, 1975-2001<sup>a</sup>

By International Classification of Childhood Cancer (ICCC) Group and Subgroup and Age

All Races, Males and Females

<u>ICCC Group and Subgroup</u>	<u>0-14</u>	<u>0-19</u>	<u>&lt;1</u>	<u>1-4</u>	<u>5-9</u>	<u>10-14</u>	<u>15-19</u>
All Groups Combined	139.1	153.6	223.5	187.4	107.5	117.9	197.0
I Leukemia	42.1	37.3	35.7	76.7	35.1	24.2	22.9
I(a) Lymphoid leukemia	33.2	27.8	18.6	65.2	28.9	16.0	11.9
Acute lymphoblastic leukemia (ALL)	32.8	27.5	18.2	64.6	28.5	15.7	11.6
Lymphoid excluding ALL	0.4	0.4	0.4	0.6	0.4	0.2	0.3
I(b) Acute non-lymphocytic leukemia	6.4	6.7	11.2	8.0	4.4	6.2	7.8
I(c) Chronic myeloid leukemia	0.9	1.2	2.0	0.9	0.6	1.0	2.1
I(d) Other specified leukemias	0.2	0.2	1.0	0.3	0.1	0.1	0.2
I(e) Unspecified leukemias	1.5	1.3	2.8	2.3	1.2	0.9	0.9
II Lymphomas and reticuloendothelial neo.	14.9	24.0	3.3	7.6	13.2	24.3	51.0
II(a) Hodgkin lymphoma	6.0	13.5	0.3	0.5	4.1	13.1	35.9
II(b) Non-Hodgkin lymphoma	5.5	7.1	1.4	4.1	5.5	7.3	12.0
II(c) Burkitt's lymphoma	2.3	2.1	0.0	2.0	2.7	2.6	1.5
II(d) Miscellaneous lymphoreticular neo.	0.4	0.3	1.5	0.4	0.2	0.3	0.3
II(e) Unspecified lymphomas	0.8	0.9	0.2	0.6	0.7	1.0	1.3
III CNS and misc intracranial and intraspinal neo.	29.4	26.8	29.5	35.1	30.0	24.4	19.1
III(a) Ependymoma	2.7	2.3	4.5	5.2	1.7	1.5	0.9
III(b) Astrocytoma	14.5	13.8	11.2	14.7	15.0	14.4	11.9
III(c) Primitive neuroectodermal tumors	6.6	5.4	8.6	9.2	7.1	3.6	2.0
III(d) Other gliomas	5.0	4.6	3.5	5.1	5.7	4.3	3.6
III(e) Misc intracranial and intraspinal neo.	0.1	0.1	0.1	0.1	0.1	0.1	0.2
III(f) Unspecified intracranial and intraspinal neo.	0.6	0.5	1.6	0.7	0.4	0.4	0.4
IV Sympathetic nervous system tumors	10.6	8.2	63.0	20.0	3.1	1.0	1.0
IV(a) Neuroblastoma and ganglioneuroblastoma	10.3	7.8	61.9	19.6	2.9	0.7	0.6
IV(b) Other sympathetic nervous system tumors	0.3	0.3	1.1	0.4	0.2	0.3	0.4
V Retinoblastoma	4.1	3.1	27.0	8.2	0.6	0.1	0.1
VI Renal tumors	8.6	6.8	20.1	18.9	6.0	1.3	1.2
VI(a) Wilms' tumor, rhabdoid and clear cell sarc.	8.3	6.3	20.1	18.7	5.7	0.9	0.3
VI(b) Renal carcinoma	0.3	0.4	0.0	0.2	0.2	0.4	0.9
VI(c) Unspecified malignant renal tumors	0.0	0.0	0.0	0.0	0.0	0.0	0.0

<sup>a</sup> SEER 9 areas. Rates are per 1,000,000 and are age-adjusted to the 2000 U.S. standard by 5-year age groups.  
 - Statistic could not be calculated.  
 Neoplasms are abbreviated as neo. Sarcomas are abbreviated as sarc.

Table XXVIII-1(cont'd)

AGE-ADJUSTED AND AGE-SPECIFIC SEER CANCER INCIDENCE RATES, 1975-2001<sup>a</sup>

By International Classification of Childhood Cancer(ICCC) Group and Subgroup and Age

All Races, Males and Females

<u>ICCC Group and Subgroup</u>	<u>0-14</u>	<u>0-19</u>	<u>&lt;1</u>	<u>1-4</u>	<u>5-9</u>	<u>10-14</u>	<u>15-19</u>
VII Hepatic tumors	1.9	1.7	9.4	3.5	0.6	0.7	1.0
VII(a) Hepatoblastoma	1.5	1.2	8.9	3.2	0.3	0.1	0.1
VII(b) Hepatic carcinoma	0.4	0.5	0.3	0.2	0.3	0.6	0.9
VII(c) Unspecified malignant hepatic tumors	0.0	0.0	0.1	0.1	0.0	0.0	0.0
VIII Malignant bone tumors	6.4	8.6	0.3	1.5	4.9	12.9	14.8
VIII(a) Osteosarcoma	3.5	4.6	0.0	0.6	2.4	7.4	8.1
VIII(b) Chondrosarcoma	0.3	0.5	0.0	0.1	0.1	0.6	1.3
VIII(c) Ewing's sarcoma	2.4	3.0	0.1	0.7	2.3	4.3	4.8
VIII(d) Other specified malignant bone tumors	0.2	0.3	0.1	0.1	0.1	0.4	0.5
VIII(e) Unspecified malignant bone tumors	0.1	0.1	0.1	0.0	0.1	0.1	0.1
IX Soft-tissue sarcomas	10.1	11.5	14.1	9.7	8.7	10.9	15.7
IX(a) Rhabdomyosarcoma and embryonal sarcoma	4.8	4.5	5.7	6.8	4.9	3.0	3.6
IX(b) Fibrosarc., neurofibrosarc. and oth fibromatous neo.	2.3	3.1	4.5	1.3	1.4	3.5	5.5
IX(c) Kaposi's sarcoma	0.0	0.0	0.0	0.0	0.0	0.0	0.2
IX(d) Other specified soft-tissue sarcomas	2.1	2.7	3.2	1.1	1.7	3.0	4.5
IX(e) Unspecified soft-tissue sarcomas	0.9	1.1	0.7	0.6	0.7	1.3	1.8
X Germ-cell, trophoblastic and other gonadal neo.	4.7	10.1	14.2	3.9	1.9	6.2	26.4
X(a) Intracranial and intraspinal germ-cell tumors	1.1	1.3	1.5	0.2	0.8	1.9	2.2
X(b) Other and unspecified non-gonadal germ-cell tumors	1.3	1.6	8.9	2.0	0.1	0.6	2.5
X(c) Gonadal germ-cell tumors	2.1	6.4	3.7	1.7	0.9	3.3	19.1
X(d) Gonadal carcinomas	0.1	0.6	0.0	0.0	0.0	0.3	2.0
X(e) Other and unspecified malignant gonadal tumors	0.1	0.2	0.1	0.1	0.1	0.2	0.6
XI Carcinomas and other malignant epithelial neo.	5.3	14.6	3.6	1.0	3.1	11.2	42.3
XI(a) Adrenocortical carcinoma	0.2	0.2	0.8	0.3	0.2	0.1	0.2
XI(b) Thyroid carcinoma	1.8	5.2	0.0	0.1	1.0	4.3	15.5
XI(c) Nasopharyngeal carcinoma	0.3	0.5	0.2	0.1	0.0	0.7	1.3
XI(d) Malignant melanoma	1.5	4.7	1.5	0.5	1.0	2.9	14.1
XI(e) Skin carcinoma	0.0	0.0	0.0	0.0	0.0	0.1	0.1
XI(f) Other and unspecified carcinomas	1.5	3.9	1.1	0.2	0.9	3.2	11.0
XII Other and unspecified malignant neo.	0.6	0.8	1.1	0.6	0.3	0.7	1.5
XII(a) Other specified malignant tumors	0.2	0.3	0.4	0.1	0.1	0.2	0.5
XII(b) Other unspecified malignant tumors	0.4	0.5	0.7	0.5	0.2	0.4	1.0
Not classified by ICCC	0.4	0.3	2.0	0.7	0.1	0.1	0.1

<sup>a</sup> SEER 9 areas. Rates are per 1,000,000 and are age-adjusted to the 2000 U.S. standard by 5-year age groups.

- Statistic could not be calculated.

Neoplasms are abbreviated as neo. Sarcomas are abbreviated as sarc.

Table XXVIII-2

AGE-ADJUSTED SEER CANCER INCIDENCE RATES, 1975-1980, 1981-1986, 1987-1992, 1993-2001<sup>a</sup>

By International Classification of Childhood Cancer (ICCC) Selected Group and Subgroup and Year of Diagnosis

All Races, Males and Females, Ages 0-19

<u>ICCC Group and Subgroup</u>	<u>1975-1980</u>	<u>1981-1986</u>	<u>1987-1992</u>	<u>1993-2001</u>
All Groups Combined	141.7	150.7	158.4	160.1
I Leukemia	34.0	37.1	38.5	38.7
I(a) Lymphoid leukemia	24.4	27.9	29.1	29.0
Acute lymphoblastic leukemia (ALL)	23.9	27.7	28.8	28.6
I(b) Acute non-lymphocytic leukemia	6.0	6.2	6.5	7.6
II Lymphomas and reticuloendothelial neo.	24.0	24.8	24.7	23.1
II(a) Hodgkin lymphoma	14.4	14.1	14.2	12.1
II(b,c,e) Non-Hodgkin lymphoma	9.1	10.1	10.2	10.9
III CNS and misc intracranial and intraspinal neo.	23.7	24.7	29.7	28.1
III(a) Ependymoma	1.9	1.9	2.8	2.3
III(b) Astrocytoma	12.3	12.6	15.8	14.2
III(c) Primitive neuroectodermal tumors	4.7	5.0	5.4	6.1
III(d) Other gliomas	4.0	4.4	5.1	4.9
IV Sympathetic nervous system tumors	7.7	8.3	7.8	8.6
IV(a) Neuroblastoma and ganglioneuroblastoma	7.6	7.7	7.5	8.3
V Retinoblastoma	2.8	2.9	3.1	3.3
VI Renal tumors	6.3	6.8	6.6	7.1
VI(a) Wilms' tumor, rhabdoid and clear cell sarcoma	5.9	6.6	6.2	6.5
VII Hepatic tumors	1.2	1.6	1.7	2.0
VII(a) Hepatoblastoma	0.7	1.1	1.2	1.5
VIII Malignant bone tumors	7.7	9.0	8.7	8.8
VIII(a) Osteosarcoma	3.8	4.9	4.9	4.8
VIII(c) Ewing's sarcoma	2.8	3.6	2.8	3.0
IX Soft-tissue sarcomas	10.4	11.0	11.4	12.4
IX(a) Rhabdomyosarcoma and embryonal sarcoma	4.2	4.1	4.7	4.8
X Germ-cell, trophoblastic and other gonadal neo.	8.7	9.9	10.5	11.0
X(a) Intracranial and intraspinal germ-cell tumors	0.8	1.1	1.3	1.9
X(c) Gonadal germ-cell tumors	5.5	6.4	6.6	6.9
XI Carcinomas and other malignant epithelial neo.	14.0	13.6	14.7	15.8
XI(b) Thyroid carcinoma	4.7	5.2	5.2	5.7
XI(d) Malignant melanoma	4.4	3.8	5.3	5.0

<sup>a</sup> SEER 9 areas. Rates are per 1,000,000 and are age-adjusted to the 2000 U.S. standard by 5-year age groups.  
 - Statistic could not be calculated.  
 Neoplasms are abbreviated as neo.

Table XXVIII-3

AGE-ADJUSTED SEER CANCER INCIDENCE TRENDS, 1975-2001, 1975-1986, 1987-2001<sup>a</sup>

By International Classification of Childhood Cancer (ICCC) Selected Group and Subgroup

All Races, Males and Females

ICCC Group and Subgroup	Ages 0-14				Ages 0-19			
	% Change 1975-2001	APC 1975-2001	APC 1975-1986	APC 1987-2001	% Change 1975-2001	APC 1975-2001	APC 1975-1986	APC 1987-2001
All Groups Combined	32.6	0.7 <sup>b</sup>	1.3 <sup>b</sup>	0.4 <sup>d</sup>	27.7	0.6 <sup>b</sup>	1.3 <sup>b</sup>	0.3 <sup>c</sup>
I Leukemia	31.5	0.7 <sup>b</sup>	1.5 <sup>b</sup>	0.3	25.8	0.6 <sup>b</sup>	1.4 <sup>b</sup>	0.4 <sup>d</sup>
I(a) Lymphoid leukemia	47.6	0.8 <sup>b</sup>	1.9 <sup>b</sup>	0.3 <sup>d</sup>	40.9	0.8 <sup>b</sup>	2.1 <sup>b</sup>	0.3 <sup>c</sup>
Acute lymphoblastic leukemia (ALL)	50.4	0.8 <sup>b</sup>	2.2 <sup>b</sup>	0.2 <sup>c</sup>	43.2	0.8 <sup>b</sup>	2.4 <sup>b</sup>	0.2 <sup>c</sup>
I(b) Acute non-lymphocytic leukemia	32.0	1.4 <sup>b</sup>	2.1	1.7	27.4	1.4 <sup>b</sup>	1.7	2.2 <sup>b</sup>
II Lymphomas and reticuloendothelial neo.	-9.3	-0.5	-0.9	-0.1	-11.8	-0.2	0.2	-0.6
II(a) Hodgkin lymphoma	-15.4	-1.1 <sup>b</sup>	-1.8	-1.1	-26.7	-0.8 <sup>b</sup>	-0.5	-1.8 <sup>b</sup>
II(b,c,e) Non-Hodgkin lymphoma	-0.3	0.3	0.0	0.8	12.0	0.9 <sup>b</sup>	1.4	1.0
III CNS & misc intracranial & intraspinal neo.	65.1	1.2 <sup>b</sup>	1.8	0.0 <sup>d</sup>	55.1	1.0 <sup>b</sup>	1.7	-0.2 <sup>d</sup>
III(a) Ependymoma	111.5	1.3	1.1	-1.1	111.6	1.2	0.4	-1.2
III(b) Astrocytoma	29.8	1.2 <sup>b</sup>	1.5	-0.8	22.3	0.8 <sup>b</sup>	1.5	-1.3 <sup>c</sup>
III(c) Primitive neuroectodermal tum.	154.1	1.3 <sup>b</sup>	0.7	1.8	174.5	1.3 <sup>b</sup>	1.4	1.7 <sup>b</sup>
III(d) Other gliomas	104.7	0.8	4.0	0.4	86.2	1.3 <sup>b</sup>	3.0	0.6
IV Sympathetic nervous system tum.	23.3	0.4	0.7	0.8	23.0	0.4	0.9	0.7
IV(a) Neuroblastoma and ganglioneuroblastoma	19.9	0.4	0.1	0.9	18.0	0.4	0.2	0.7
V Retinoblastoma	21.4	0.8	1.3	0.4	21.4	0.9	1.3	0.3
VI Renal tum.	29.0	0.4	1.4	0.2	22.0	0.5	1.3	0.2
VI(a) Wilms' tum., rhabdoid & clear cell sarcoma	28.3	0.3	1.6	0.1	28.3	0.3	1.7	0.0
VII Hepatic tum.	146.8	2.4 <sup>b</sup>	4.9	3.3	210.7	2.4 <sup>b</sup>	4.5	3.5
VII(a) Hepatoblastoma	270.7	3.2 <sup>b</sup>	7.3	3.7 <sup>b</sup>	270.7	3.0 <sup>b</sup>	7.3	3.4 <sup>b</sup>
VIII Malignant bone tum.	34.3	0.3	3.4 <sup>b</sup>	-0.4 <sup>d</sup>	27.3	0.5	2.9 <sup>b</sup>	-0.3 <sup>c</sup>
VIII(a) Osteosarcoma	109.2	1.2 <sup>b</sup>	4.5 <sup>b</sup>	0.1 <sup>c</sup>	38.5	0.8	4.2 <sup>b</sup>	-0.6 <sup>c</sup>
VIII(c) Ewing's sarcoma	28.3	-0.6	4.5	-0.2	53.0	0.1	4.3	0.8
IX Soft-tissue sarcomas	40.2	1.1 <sup>b</sup>	2.1	1.1	54.4	1.0 <sup>b</sup>	2.2	1.4 <sup>b</sup>
IX(a) Rhabdomyosarcoma and embryonal sarcoma	34.1	0.7	1.6	-0.5	68.5	0.7	1.6	-0.6
X Germ-cell, trophoblastic & other gonadal neo.	44.8	1.3 <sup>b</sup>	1.2	0.5	49.3	1.1 <sup>b</sup>	1.6	0.7
X(a) Intracranial and intraspinal germ-cell tum.	117.1	-	-	3.3	173.8	3.9 <sup>b</sup>	4.1	3.6
X(c) Gonadal germ-cell tum.	-10.6	-0.5	-1.0	-0.1	57.9	1.0 <sup>b</sup>	1.9	0.9
XI Carcinomas and other malignant epithelial neo.	28.0	0.9 <sup>b</sup>	-0.1	2.9 <sup>b</sup>	35.7	0.8 <sup>b</sup>	0.6	1.1
XI(b) Thyroid carcinoma	50.9	0.5	0.5	1.9	60.1	1.0 <sup>b</sup>	1.4	1.8
XI(d) Malignant melanoma	99.9	1.8 <sup>b</sup>	-1.2	2.4	69.1	1.1	0.2	-0.1

<sup>a</sup> The APC is the Annual Percent Change over the time interval.

<sup>b</sup> SEER 9 areas.

<sup>c</sup> The APC is significantly different from zero (p<.05).

<sup>d</sup> The APC for 1987-2001 is significantly different from the APC for 1975-1986 (p<.05).

<sup>e</sup> The APC for 1987-2001 is significantly different from the APC for 1975-1986 (p<.10).

- Statistic could not be calculated.

Neoplasms are abbreviated as neo. Tumors are abbreviated as tum.

Table XXVIII-4

AGE-ADJUSTED SEER CANCER INCIDENCE TRENDS, 1975-2001, 1975-1986, 1987-2001<sup>a</sup>

By International Classification of Childhood Cancer (ICCC) Selected Group and Subgroup

All Races, Males

ICCC Group and Subgroup	Ages 0-14				Ages 0-19			
	% Change 1975-2001	APC 1975-2001	APC 1975-1986	APC 1987-2001	% Change 1975-2001	APC 1975-2001	APC 1975-1986	APC 1987-2001
All Groups Combined	24.8	0.7 <sup>b</sup>	1.4 <sup>b</sup>	0.3 <sup>c</sup>	25.3	0.7 <sup>b</sup>	1.7 <sup>b</sup>	0.2 <sup>c</sup>
I Leukemia	17.2	0.7 <sup>b</sup>	1.4	0.3	11.2	0.5 <sup>b</sup>	1.3 <sup>b</sup>	0.3
I(a) Lymphoid leukemia	33.5	0.8 <sup>b</sup>	1.8 <sup>b</sup>	0.1	28.9	0.7 <sup>b</sup>	2.3 <sup>b</sup>	0.0 <sup>c</sup>
Acute lymphoblastic leukemia (ALL)	34.3	0.9 <sup>b</sup>	2.1 <sup>b</sup>	0.0 <sup>d</sup>	29.5	0.8 <sup>b</sup>	2.7 <sup>b</sup>	-0.1 <sup>c</sup>
I(b) Acute non-lymphocytic leukemia	41.3	2.0 <sup>b</sup>	3.1	3.8 <sup>b</sup>	27.7	1.5 <sup>b</sup>	1.1	3.9 <sup>b</sup>
II Lymphomas and reticuloendothelial neo.	-25.2	-0.6	-0.2	-0.6	-24.5	-0.3	0.8	-0.8
II(a) Hodgkin lymphoma	-7.7	-1.3 <sup>b</sup>	-0.4	-1.8	-34.4	-1.2 <sup>b</sup>	0.0	-2.4 <sup>b</sup>
II(b,c,e) Non-Hodgkin lymphoma	-31.7	0.0	0.0	0.1	-12.4	0.7	1.6	0.8
III CNS & misc intracranial & intraspinal neo.	86.1	1.3 <sup>b</sup>	2.7 <sup>b</sup>	0.0 <sup>c</sup>	71.6	1.1 <sup>b</sup>	2.6 <sup>b</sup>	0.0 <sup>c</sup>
III(a) Ependymoma	92.5	1.0	-1.3	-2.5	136.7	1.0	-1.5	-2.0
III(b) Astrocytoma	37.6	1.2 <sup>b</sup>	2.1	-1.0	30.9	0.8	2.1	-1.2 <sup>c</sup>
III(c) Primitive neuroectodermal tum.	409.1	1.5 <sup>b</sup>	0.6	1.7	426.3	1.5 <sup>b</sup>	1.3	1.9
III(d) Other gliomas	117.0	1.1	8.2 <sup>b</sup>	0.6 <sup>c</sup>	65.1	1.5 <sup>b</sup>	5.8	0.6 <sup>d</sup>
IV Sympathetic nervous system tum.	45.8	0.4	0.4	-0.2	44.3	0.5	0.7	-0.4
IV(a) Neuroblastoma and ganglioneuroblastoma	42.3	0.4	-0.4	-0.2	37.4	0.4	-0.2	-0.4
V Retinoblastoma	22.2	1.3	1.1	-0.1	22.2	1.3	1.1	-0.3
VI Renal tum.	4.3	0.6	3.2	-0.4	-0.6	0.6	2.3	0.0
VI(a) Wilms' tum., rhabdoid & clear cell sarcoma	-0.3	0.5	3.7	-0.4	-0.3	0.5	3.6	-0.4 <sup>d</sup>
VII Hepatic tum.	11.2	2.6 <sup>b</sup>	4.7	2.0	39.6	2.6 <sup>b</sup>	3.0	1.9
VII(a) Hepatoblastoma	25.6	3.0 <sup>b</sup>	7.1	2.3	25.6	2.9 <sup>b</sup>	6.8	2.0
VIII Malignant bone tum.	20.4	1.0	5.2 <sup>b</sup>	1.4	40.1	1.2 <sup>b</sup>	4.3 <sup>b</sup>	1.0
VIII(a) Osteosarcoma	45.1	1.4	8.2 <sup>b</sup>	1.2 <sup>d</sup>	68.4	1.4	7.8 <sup>b</sup>	0.3 <sup>c</sup>
VIII(c) Ewing's sarcoma	70.4	0.7	5.1	3.4	45.6	0.9	3.1	3.3
IX Soft-tissue sarcomas	53.0	1.2 <sup>b</sup>	1.2	1.0	67.8	1.2 <sup>b</sup>	1.4	0.8
IX(a) Rhabdomyosarcoma and embryonal sarcoma	75.7	1.1	2.9	0.0	118.9	0.9	2.5	-0.6
X Germ-cell, trophoblastic & other gonadal neo.	23.2	1.6	-0.7	1.3	92.8	1.4 <sup>b</sup>	2.2	1.3
X(a) Intracranial and intraspinal germ-cell tum.	58.1	-	-	4.5	116.4	4.1 <sup>b</sup>	2.9	3.9
X(c) Gonadal germ-cell tum. (testis)	-2.4	-0.8	-3.2	-1.0	105.8	1.1 <sup>b</sup>	2.1	1.7
XI Carcinomas and other malignant epithelial neo.	3.3	0.8	-1.5	2.5	34.1	0.8 <sup>b</sup>	1.4	1.0
XI(b) Thyroid carcinoma	49.9	-	-	-	32.4	0.0	2.8	2.7
XI(d) Malignant melanoma	14.9	0.5	-5.3	1.7	31.3	1.2	0.4	0.3

<sup>a</sup> The APC is the Annual Percent Change over the time interval.

<sup>b</sup> SEER 9 areas.

<sup>c</sup> The APC is significantly different from zero (p<.05).

<sup>d</sup> The APC for 1987-2001 is significantly different from the APC for 1975-1986 (p<.05).

<sup>e</sup> The APC for 1987-2001 is significantly different from the APC for 1975-1986 (p<.10).

- Statistic could not be calculated.

Neoplasms are abbreviated as neo. Tumors are abbreviated as tum.

Table XXVIII-5

AGE-ADJUSTED SEER CANCER INCIDENCE TRENDS, 1975-2001, 1975-1986, 1987-2001<sup>a</sup>

By International Classification of Childhood Cancer (ICCC) Selected Group and Subgroup

All Races, Females

ICCC Group and Subgroup	Ages 0-14				Ages 0-19			
	% Change	APC	APC	APC	% Change	APC	APC	APC
	1975-2001	1975-2001	1975-1986	1987-2001	1975-2001	1975-2001	1975-1986	1987-2001
All Groups Combined	42.3	0.7 <sup>b</sup>	1.1	0.6	30.5	0.6 <sup>b</sup>	1.0	0.4
I Leukemia	54.2	0.6 <sup>b</sup>	1.8	0.1	48.4	0.7 <sup>b</sup>	1.7	0.4
I(a) Lymphoid leukemia	68.4	0.8 <sup>b</sup>	2.2	0.5	58.3	0.8 <sup>b</sup>	2.0	0.7
Acute lymphoblastic leukemia (ALL)	75.5	0.8 <sup>b</sup>	2.4	0.4	63.8	0.8 <sup>b</sup>	2.1	0.6
I(b) Acute non-lymphocytic leukemia	20.2	0.8	1.4	-0.7	26.6	1.2 <sup>b</sup>	2.9	0.4
II Lymphomas and reticuloendothelial neo.	21.9	-0.3	-2.3	1.1	7.5	-0.1	-0.4	-0.3
II(a) Hodgkin lymphoma	-25.7	-0.9	-3.8	-0.5	-16.9	-0.5	-0.9	-1.2
II(b,c,e) Non-Hodgkin lymphoma	89.5	1.2	1.2	3.4	62.4	1.2 <sup>b</sup>	1.5	1.8
III CNS & misc intracranial & intraspinal neo.	45.6	1.0 <sup>b</sup>	0.8	0.0	37.2	0.8 <sup>b</sup>	0.5	-0.6
III(a) Ependymoma	137.8	1.2	2.0	0.4	85.5	0.8	0.2	-0.4
III(b) Astrocytoma	22.6	1.2 <sup>b</sup>	1.2	-0.8	13.2	0.8	0.7	-1.5
III(c) Primitive neuroectodermal tum.	28.5	0.9	0.5	1.5	28.5	0.8	1.3	1.2
III(d) Other gliomas	92.8	0.4	-0.3	0.5	114.0	0.8	0.3	0.6
IV Sympathetic nervous system tum.	3.3	0.5	0.9	2.4 <sup>b</sup>	3.3	0.4	1.0	2.4 <sup>b</sup>
IV(a) Neuroblastoma and ganglioneuroblastoma	0.1	0.5	0.7	2.4 <sup>b</sup>	0.1	0.4	0.6	2.3 <sup>b</sup>
V Retinoblastoma	20.0	0.5	0.8	1.7	20.0	0.6	0.8	1.8
VI Renal tum.	57.4	0.3	-0.4	0.7	48.8	0.4	0.3	0.4
VI(a) Wilms' tum., rhabdoid & clear cell sarcoma	57.4	0.1	-0.4	0.4	57.4	0.2	0.0	0.3
VII Hepatic tum.	544.0	2.0	3.6	4.9 <sup>b</sup>	712.9	2.2 <sup>b</sup>	6.3	5.6 <sup>b</sup>
VII(a) Hepatoblastoma	-	-	-	4.7	-	-	-	4.7
VIII Malignant bone tum.	53.9	-0.4	1.7	-2.6	10.8	-0.7	1.2	-2.4
VIII(a) Osteosarcoma	163.1	0.8	-0.2	-1.0	18.9	-0.1	-0.2	-2.0
VIII(c) Ewing's sarcoma	-32.5	-2.1	6.0	-4.5 <sup>c</sup>	70.0	-1.4	7.7	-3.3 <sup>c</sup>
IX Soft-tissue sarcomas	24.8	1.0	3.1	1.2	38.5	0.8	3.2	2.1 <sup>b</sup>
IX(a) Rhabdomyosarcoma and embryonal sarcoma	-12.3	0.0	-0.5	-1.6	7.9	0.4	0.1	-0.6
X Germ-cell, trophoblastic & other gonadal neo.	64.7	1.0	3.2	-0.5	14.4	0.4	0.6	-0.5
X(a) Intracranial and intraspinal germ-cell tum.	302.8	-	-	-	512.6	-	-	-
X(c) Gonadal germ-cell tum. (ovary)	-17.2	-0.3	1.9	0.5	3.8	0.6	1.7	-0.8
XI Carcinomas and other malignant epithelial neo.	46.8	1.0 <sup>b</sup>	0.9	2.9	37.5	0.8 <sup>b</sup>	0.3	1.1
XI(b) Thyroid carcinoma	51.5	0.6	2.3	2.2	70.2	1.3 <sup>b</sup>	1.5	1.7
XI(d) Malignant melanoma	213.5	-	-	2.7	108.4	1.1	0.3	-0.2

<sup>a</sup> The APC is the Annual Percent Change over the time interval.

SEER 9 areas.

<sup>b</sup> The APC is significantly different from zero (p<.05).

<sup>c</sup> The APC for 1987-2001 is significantly different from the APC for 1975-1986 (p<.05).

<sup>d</sup> The APC for 1987-2001 is significantly different from the APC for 1975-1986 (p<.10).

- Statistic could not be calculated.

Neoplasms are abbreviated as neo. Tumors are abbreviated as tum.

Table XXVIII-6

5-YEAR RELATIVE SURVIVAL RATES, 1985-2000<sup>a</sup>

By International Classification of Childhood Cancer (ICCC) Selected Group and Subgroup and Sex and Age

ICCC Group & Subgroup	Ages 0-19 by Sex			Both Sexes by Age					
	Total	Male	Female	<1	1-4	5-9	10-14	15-19	0-14
All Groups Combined	76.1	74.2	78.3	72.2	76.4	75.2	75.1	77.9	75.3
I Leukemia	71.1	69.3	73.4	44.7	82.0	77.0	61.6	47.8	74.9
I(a) Lymphoid leukemia	79.4	77.8	81.6	44.1	87.9	82.1	70.8	54.5	82.1
Acute lymphoblastic leukemia (ALL)	79.4	77.8	81.7	44.2	87.9	82.2	70.7	54.5	82.1
I(b) Acute non-lymphocytic leukemia	41.8	37.2	46.4	39.6 <sup>b</sup>	43.5	49.0	38.5	39.2	42.8
II Lymphomas & reticuloendothelial neo.	85.0	83.3	87.4	-	78.0	84.5	86.1	85.6	84.3
II(a) Hodgkin lymphoma	93.0	92.6	93.4	-	-	93.5	93.6	92.6	93.8
II(b,c,e) Non-Hodgkin lymphoma	75.2	75.0	75.6	-	75.7	81.0	78.0	70.1	78.4
III CNS and misc intracranial & intraspinal neo.	68.7	69.6	67.6	51.3	64.0	68.2	74.1	76.0	67.2
III(a) Ependymoma	63.4	66.3	58.5 <sup>b</sup>	36.6 <sup>b</sup>	55.1	77.3 <sup>b</sup>	74.2 <sup>b</sup>	92.3 <sup>b</sup>	60.2
III(b) Astrocytoma	78.1	77.8	78.5	75.4 <sup>b</sup>	84.0	76.1	77.6	75.5	78.8
III(c) Primitive neuroectodermal tumors	58.5	61.5	53.8	21.1 <sup>b</sup>	48.2	72.1	66.5	73.1 <sup>b</sup>	57.1
III(d) Other gliomas	58.4	61.6	54.5	-	51.4	40.9	69.0	76.7	53.8
IV Sympathetic nervous system tumors	66.0	64.4	67.7	85.8	55.4	45.9 <sup>b</sup>	62.1 <sup>c</sup>	47.2 <sup>c</sup>	66.5
IV(a) Neuroblastoma and ganglioneuroblastoma	65.9	64.5	67.4	86.1	54.9	44.6 <sup>b</sup>	-	-	66.5
V Retinoblastoma	95.4	96.0	94.8	95.3	94.8	-	-	-	95.4
VI Renal tumors	90.1	89.1	91.0	88.9	92.5	88.5	81.7 <sup>b</sup>	77.4 <sup>b</sup>	90.6
VI(a) Wilms' tumor, rhabdoid & clear cell sarcoma	90.7	89.9	91.4	88.9	92.5	88.1	-	-	90.9
VII Hepatic tumors	50.6	49.3	52.1 <sup>b</sup>	68.1 <sup>b</sup>	54.3 <sup>b</sup>	-	-	17.5 <sup>b</sup>	55.9
VII(a) Hepatoblastoma	60.5	57.0 <sup>b</sup>	64.4 <sup>b</sup>	68.6 <sup>b</sup>	56.3 <sup>b</sup>	-	-	-	60.9
VIII Malignant bone tumors	65.4	63.1	69.0	-	-	71.3	67.8	61.6	68.3
VIII(a) Osteosarcoma	64.3	61.9	68.1	-	-	64.3 <sup>b</sup>	69.5	60.0	67.8
VIII(c) Ewing's sarcoma	61.5	57.8	67.0	-	-	76.1 <sup>b</sup>	60.5	56.0	65.4
IX Soft-tissue sarcomas	71.4	71.2	71.7	59.5 <sup>b</sup>	78.4	73.9	74.5	66.2	73.9
IX(a) Rhabdomyosarcoma & embryonal sarcoma	64.9	66.9	61.7	46.2 <sup>b</sup>	82.1	68.2	55.1 <sup>b</sup>	47.5 <sup>b</sup>	69.0
X Germ-cell, trophoblastic & other gonadal neo.	89.1	88.4	90.1	81.9	94.0	84.6 <sup>b</sup>	87.0	90.2	87.0
X(a) Intracranial & intraspinal germ-cell tumors	79.1	78.3	81.7 <sup>b</sup>	-	-	76.5 <sup>b</sup>	84.0	84.4	75.7
X(c) Gonadal germ-cell tumors	94.8	94.7	94.9	-	100.0	-	96.2	93.8	98.2
XI Carcinomas & other malignant epithelial neo.	89.8	83.3	93.0	-	-	91.5	91.3	89.8	89.8
XI(b) Thyroid carcinoma	98.8	96.5	99.2	-	-	-	97.0	99.2	97.5
XI(d) Malignant melanoma	92.5	89.9	94.3	-	-	-	88.9	93.6	89.0

<sup>a</sup> Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

<sup>b</sup> The standard error of the survival rate is between 5 and 10 percentage points.


<sup>c</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Neoplasms are abbreviated as neo.

Survival rates are relative rates expressed as percents.


# SEER Incidence and US Mortality All Childhood Cancers, Under 20 Years of Age Both Sexes, All Races, 1975-2001



Source: SEER 9 areas and NCHS public use data file for the total US. Rates are age-adjusted to the 2000 US standard million population by 5-year age groups. Regression lines are calculated using the Joinpoint Regression Program Version 2.7, September 2003, National Cancer Institute.




# SEER Incidence and US Mortality Brain and CNS, Under 15 Years of Age Both Sexes, All Races, 1975-2001




Source: SEER 9 areas and NCHS public use data file for the total US. Rates are age-adjusted to the 2000 US standard million population by 5-year age groups. Regression lines are calculated using the Joinpoint Regression Program Version 2.7, September 2003, National Cancer Institute.

# Childhood Cancer SEER Incidence Rates by ICCC Group, 1975-2001 Under 20 Years of Age, Both Sexes, All Races



Source: SEER 9 areas. Rates are age-adjusted to the 2000 US standard million population by 5-year age groups.


# Childhood Cancer SEER Incidence Rates 1992-2001 by ICCG Group and Race/Ethnicity Both Sexes, Under 20 Years of Age



Source: SEER 12 areas. Incidence rates are age-adjusted to the 2000 US standard million population by 5-year age groups and are not shown for fewer than 10 cases for the time period.

<sup>^^</sup> Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Hispanic rates exclude cases diagnosed in Detroit and Hawaii.

# SEER Childhood Cancer 1990-2000 5-Year Observed Survival Rates by ICCC Group and Race/Ethnicity Both Sexes, Under 20 Years of Age



Source: SEER 12 areas.

^^ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Hispanic rates exclude cases diagnosed in Detroit and Hawaii.